Copyright
©2005 Baishideng Publishing Group Inc.
World J Gastroenterol. Feb 28, 2005; 11(8): 1141-1148
Published online Feb 28, 2005. doi: 10.3748/wjg.v11.i8.1141
Published online Feb 28, 2005. doi: 10.3748/wjg.v11.i8.1141
Figure 1 Serum ALT and AST levels in the CCl4- or CCl4 with silymarin-treated groups.
A: Serum ALT levels were detected at 4, 8, and 12 wk; B: Serum AST levels were detected at 4, 8, and 12 wk. In the CCl4 with silymarin-treated group (black bar), increase of serum ALT and AST levels were lower than those of CCl4-treated group (open bar).
- Citation: Jeong DH, Lee GP, Jeong WI, Do SH, Yang HJ, Yuan DW, Park HY, Kim KJ, Jeong KS. Alterations of mast cells and TGF-β1 on the silymarin treatment for CCl4-induced hepatic fibrosis. World J Gastroenterol 2005; 11(8): 1141-1148
- URL: https://www.wjgnet.com/1007-9327/full/v11/i8/1141.htm
- DOI: https://dx.doi.org/10.3748/wjg.v11.i8.1141